199 related articles for article (PubMed ID: 37702298)
21. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
22. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.
Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z
J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152
[TBL] [Abstract][Full Text] [Related]
23. PARP Inhibitor Efficacy Depends on CD8
Pantelidou C; Sonzogni O; De Oliveria Taveira M; Mehta AK; Kothari A; Wang D; Visal T; Li MK; Pinto J; Castrillon JA; Cheney EM; Bouwman P; Jonkers J; Rottenberg S; Guerriero JL; Wulf GM; Shapiro GI
Cancer Discov; 2019 Jun; 9(6):722-737. PubMed ID: 31015319
[TBL] [Abstract][Full Text] [Related]
24. Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor.
Yi XF; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Han CB; Ma JT
Biomed Pharmacother; 2023 Jul; 163():114770. PubMed ID: 37105074
[TBL] [Abstract][Full Text] [Related]
25. Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS-STING pathway.
Guo Y; Shen R; Wang F; Wang Y; Xia P; Wu R; Liu X; Ye W; Tian Y; Wang D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6315-6328. PubMed ID: 36745223
[TBL] [Abstract][Full Text] [Related]
26. Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.
Kumar T; Hobbs E; Yang F; Chang JT; Contreras A; Cuentas ERP; Garber H; Lee S; Lu Y; Scoggins ME; Adrada BE; Whitman GJ; Arun BK; Mittendorf EA; Litton JK
Clin Cancer Res; 2022 Sep; 28(17):3669-3676. PubMed ID: 35736816
[TBL] [Abstract][Full Text] [Related]
27. Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
Alvarado-Cruz I; Mahmoud M; Khan M; Zhao S; Oeck S; Meas R; Clairmont K; Quintana V; Zhu Y; Porciuncula A; Wyatt H; Ma S; Shyr Y; Kong Y; LoRusso PM; Laverty D; Nagel ZD; Schalper KA; Krauthammer M; Sweasy JB
Biochem Pharmacol; 2021 Feb; 184():114359. PubMed ID: 33285109
[TBL] [Abstract][Full Text] [Related]
28. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
[TBL] [Abstract][Full Text] [Related]
29. Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
Seyedin SN; Hasibuzzaman MM; Pham V; Petronek MS; Callaghan C; Kalen AL; Mapuskar KA; Mott SL; Spitz DR; Allen BG; Caster JM
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):81-92. PubMed ID: 32036006
[TBL] [Abstract][Full Text] [Related]
30. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
[TBL] [Abstract][Full Text] [Related]
31. A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.
Tian C; Wei Y; Li J; Huang Z; Wang Q; Lin Y; Lv X; Chen Y; Fan Y; Sun P; Xiang R; Chang A; Yang S
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270034
[TBL] [Abstract][Full Text] [Related]
32. Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1.
Noh JY; Lee IP; Han NR; Kim M; Min YK; Lee SY; Yun SH; Kim SI; Park T; Chung H; Park D; Lee CH
Cell Mol Gastroenterol Hepatol; 2022; 14(4):769-788. PubMed ID: 35843546
[TBL] [Abstract][Full Text] [Related]
33. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
34. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Higuchi T; Flies DB; Marjon NA; Mantia-Smaldone G; Ronner L; Gimotty PA; Adams SF
Cancer Immunol Res; 2015 Nov; 3(11):1257-68. PubMed ID: 26138335
[TBL] [Abstract][Full Text] [Related]
35. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.
Wang Q; Bergholz JS; Ding L; Lin Z; Kabraji SK; Hughes ME; He X; Xie S; Jiang T; Wang W; Zoeller JJ; Kim HJ; Roberts TM; Konstantinopoulos PA; Matulonis UA; Dillon DA; Winer EP; Lin NU; Zhao JJ
Nat Commun; 2022 May; 13(1):3022. PubMed ID: 35641483
[TBL] [Abstract][Full Text] [Related]
36. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
38. Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.
Demeule M; Currie JC; Charfi C; Zgheib A; Cousineau I; Lullier V; Béliveau R; Marsolais C; Annabi B
Front Immunol; 2024; 15():1355945. PubMed ID: 38482021
[TBL] [Abstract][Full Text] [Related]
39. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
40. Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer.
Zhu Q; Dai Q; Zhao L; Zheng C; Li Q; Yuan Z; Li L; Xie Z; Qiu Z; Huang W; Liu G; Zu X; Chu B; Jiang Y
Cell Death Dis; 2024 Jan; 15(1):10. PubMed ID: 38182579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]